230 related articles for article (PubMed ID: 30176784)
1. Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Wu HL
J Oncol Pharm Pract; 2019 Sep; 25(6):1388-1395. PubMed ID: 30176784
[TBL] [Abstract][Full Text] [Related]
2. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
3. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
5. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
[TBL] [Abstract][Full Text] [Related]
6. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
7. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment.
Kim JJ; Kang J; Hong YS; Kim KP; Kim SY; Kim TW; Kim JE
Med Oncol; 2018 Apr; 35(5):65. PubMed ID: 29623500
[TBL] [Abstract][Full Text] [Related]
9. A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.
McElroy TM; Gruenigen VE; Waggoner SE
Gynecol Oncol; 2003 Nov; 91(2):435-7. PubMed ID: 14599880
[TBL] [Abstract][Full Text] [Related]
10. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Zhou JN; Huang XE; Ye Z; Li C; Zhang Q; Lin Y; Jiang W; Sunh WL; Shi MQ; Shu YQ
Asian Pac J Cancer Prev; 2009; 10(6):1147-50. PubMed ID: 20192601
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Jones R; Ryan M; Friedlander M
Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma.
Shah AC; Minturn JE; Li Y; Belasco JB; Phillips PC; Kang TI; Cole KA; Waanders AJ; Pollack R; Didomenico C; Wildes C; Fisher MJ
Pediatr Blood Cancer; 2016 Jan; 63(1):21-6. PubMed ID: 26235452
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
15. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
16. A new rapid desensitization protocol for chemotherapy agents.
Gastaminza G; de la Borbolla JM; Goikoetxea MJ; Escudero R; Antón J; Espinós J; Lacasa C; Fernández-Benítez M; Sanz ML; Ferrer M
J Investig Allergol Clin Immunol; 2011; 21(2):108-12. PubMed ID: 21462800
[TBL] [Abstract][Full Text] [Related]
17. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
19. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
